/PRNewswire/ Illumina, Inc. (NASDAQ:ILMN) today announced the launch of TruSightâ„¢ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple.
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
SAN DIEGO, March 15, 2022. | March 15, 2022
/PRNewswire/ Illumina, Inc. (NASDAQ:ILMN) today announced the launch of TruSightâ„¢ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple.